You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that Fractured Truth—an unbranded patient campaign aimed to educate younger postmenopausal women about risks associated with osteoporosis—won the Bronze Healthcare/Pharmaceutical Industry Pearl
-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017- -Median PFS was 5.4 months and Clinical Benefit Rate at 24 weeks was 47.4% - -38% of study patients
SABCS to include five abstracts from the development program for elacestrant as a potential treatment of ER-positive advanced breast cancer Radius to host live webcast to discuss data presented at SABCS and provide a company update on December 7 th at 8:00 p.m. CT / 9:00 p.m.
WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced that its Board of Directors granted Joseph Kelly, in connection with his appointment as the Company's Senior Vice President of Sales and Marketing, an option to purchase
WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and the promotion of Amanda Mott to Senior Vice President of Market Access. Mr.
First full quarter of TYMLOS™ sales shows accelerating market share & stabilization of the anabolic market Plan access at approximately 200 million lives — 87% commercial and 35% Medicare Male Osteo Trial: FDA agreement on the design of a clinical trial in men FDA Fast Track Designation for
- Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018 - - Phase 2 Study is a potentially pivotal trial for accelerated approval - WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc.
Five posters will cover new data on the need for osteoporosis awareness as well as cost-effectiveness data on treatment with TYMLOS WALTHAM, Mass., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing and
WALTHAM, Mass., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The Company will host a conference call and live audio webcast at 4:30 p.m.